Dominant mutations in superoxide dismutase cause amyotrophic lateral sclerosis (ALS), an adult-onset neurodegenerative disease that is characterized by the loss of motor neurons. Using mice carrying a deletable mutant gene, diminished mutant expression in astrocytes did not affect onset, but delayed microglial activation and sharply slowed later disease progression. These findings demonstrate that mutant astrocytes are viable targets for therapies for slowing the progression of non-cell autonomous killing of motor neurons in ALS.
ALS is an adult-onset neurodegenerative disease, characterized by a progressive and fatal loss of motor neurons. Dominant mutations in the gene for superoxide dismutase (SOD1) are the most frequent cause of inherited ALS. Ubiquitous expression of mutant SOD1 in rodents leads to progressive, selective motor neuron degeneration as a result of acquired toxic properties. The exact mechanism responsible for motor neuron degeneration in ALS, however, is not known 1, 2 . Mutant damage in the vulnerable motor neurons is a key determinant of disease onset 3 , whereas accumulating evidence supports an active role of nonneuronal cells in motor neuron degeneration [3] [4] [5] [6] [7] . Evidence with selective gene excision 3 or bone-marrow grafting 5 has demonstrated that mutant SOD1-derived damage in microglia accelerates later disease progression. Despite the importance of astrocyte function, the role of mutant action in astrocytes in disease has not been tested in vivo.
To examine whether mutant SOD1 damage in astrocytes contributes to disease, loxSOD1 G37R mice 3 , carrying a mutant SOD1 gene that can be deleted by the action of the Cre recombinase, were mated with GFAP-Cre mice ( Fig. 1 and Supplementary Fig. 1 online) , which express both Cre recombinase and b-galactosidase (LacZ) under the control of the human GFAP promoter 8 . Mice from these matings that carry the GFAP-Cre transgene are denoted as Cre + , whereas mice without it are referred to as Cre -. To determine the cell-type specificity of Cre expression in the spinal cord, GFAP-Cre mice were mated to Rosa26 mice, which ubiquitously express a LacZ gene that encodes functional b-galactosidase only after Cre-mediated recombination. Although this GFAP-Cre transgene is expressed in a subset of neurons in the cerebellum and hippocampus during embryogenesis 9 , measurement of b-galactosidase activity (by deposition of a blue reaction product after addition of the X-gal substrate) demonstrated that Cre expression and Cre-mediated recombination was restricted in the spinal cord to GFAP-reactive astrocytes (Fig. 1a,b) . The efficiency of mutant gene excision in cultured astrocytes from newborn loxSOD1 G37R /GFAP-Cre + mice was B76% (Fig. 1d,e) , determined by quantitative PCR for human SOD1 transgene number (Fig. 1d) and immunoblotting for mutant SOD1 levels (Fig. 1e) . We observed neither detectable Cre activity nor mutant gene excision in microglia ( Fig. 1c and Supplementary Fig. 2 online) .
A simple, objective measure of disease onset and early disease was applied by initiation of weight loss, itself reflecting denervationinduced muscle atrophy. Reduction of SOD1 G37R in astrocytes did not slow disease onset nor early disease (GFAP-Cre + , 341.6 ± 48. Fig. 1g ). This contrasts with delayed disease onset from diminished mutant synthesis solely within motor neurons (with a VAChT-Cre transgene carrying the motor neuron-specific vesicular acetylcholine transporter promoter) without affecting disease progression (Supplementary Results, Supplementary Methods and Supplementary Fig. 3 online), just as reported previously with an Isl1 (Islet1)-Cre transgene that is expressed in motor neurons and some peripheral tissues 3 .
Astrocytic and microglial cell activation is a well-accepted feature of SOD1 mutant-mediated ALS 1,2 . An elevated proportion of GFAP-positive astrocytes appeared before disease onset (Fig. 2a) in loxSOD1 G37R mice. This astrogliosis was progressive, readily apparent by onset (Fig. 2b) and more prominent during disease progression (Fig. 2c) . Despite substantial mutant reduction, astrogliosis was not, however, different in comparing disease-matched loxSOD1 G37R /GFAPCre + mice (Fig. 2d,e) and loxSOD1 G37R /GFAP-Cre -mice (Fig. 2b,c) .
Microglial activation occurred at earliest disease onset in Cre -mice (Fig. 2g) and was progressively more prominent during disease progression (Fig. 2h) . Microglial activation was, however, substantially delayed from onset through early disease in the GFAP-Cre + mice when mutant SOD1 levels were reduced only in astrocytes (Fig. 2i,j) . By exploiting the presence of b-galactosidase to mark astrocytes with diminished SOD1 mutant synthesis, examination of sections throughout lumbar spinal cords of symptomatic loxSOD1 G37R /GFAP-Cre + mice revealed an inverse relationship (Fig. 3a-g ) between the number of astrocytes with reduced mutant SOD1 (Cre + ) and activated microglia (correlation coefficient, r ¼ -0.868, P o 0.001), despite comparable astrocytic activation. Thus, microglial activation was most prominent in areas with the highest mutant SOD1-expressing astrocyte concentration.
Elevated production of nitric oxide by upregulated inducible nitric oxide synthase (iNOS) has been reported in mutant SOD1 mice 10 , although deletion of the iNOS gene has modest 11 or no 12 effect on SOD1-mediated disease. It is not known in which glial cells this nitric oxide is produced in in vivo models of ALS, although both microglia and astrocytes have an ability to produce it when stimulated in vitro 13 . Triple staining of lumbar spinal cord sections with iNOS, Mac2 and GFAP antibodies (Fig. 3h-r) revealed that almost all iNOS-positive cells were Mac2-positive microglia (Fig. 3n-r and Supplementary Fig. 4 online), indicating that activated microglia are the primary cell type producing nitric oxide in this SOD1 mouse model. Diminishing mutant synthesis in astrocytes inhibited iNOS induction in disease-matched, symptomatic SOD1 mice (Fig. 3h,k) , consistent with substantial inhibition of microglial activation (Fig. 3i,l) . ) loxSOD1 G37R transgene levels (n ¼ 3 for each group) in primary microglia (c) or astrocytes (d) from loxSOD1 G37R /GFAP-Cre + and loxSOD1 G37R mice using real-time PCR. (e) We determined SOD1 G37R and mouse SOD1 levels by immunoblotting extracts from isolated primary astrocytes of loxSOD1 G37R /GFAP-Cre + (lanes 1, 2) and a dilution series of a comparable extract from LoxSOD1 G37R astrocytes representing 25%, 50% and 100% of the protein amounts loaded in lanes 1 and 2 (lanes 3-5). (f,g) Ages at which early disease phase (to 10% weight loss, P ¼ 0.76; f) or end-stage disease (P o 0.0001; g) were reached for loxSOD1 G37R /GFAP-Cre + mice (red) and loxSOD1 G37R littermates (blue). Mean ages ± s.d. are provided. (h-j) Mean onset (P ¼ 0.47) (h), mean duration of early disease (from onset to 10% weight loss, P ¼ 0.35; i) and a late disease (from 10% weight loss to end stage, P o 0.0001; j) for loxSOD1 G37R /GFAP-Cre + (red) and loxSOD1 G37R littermates (blue). At each time point, P value was determined by unpaired t-test. Error bars denote s.d. A role for astrocytes in inherited ALS has been previously considered in several contexts. Mutant-expressing astrocytes produce and release one or more as yet uncharacterized components that can accelerate motor neuron death in vitro 6, 7 . Focal loss of the astrocytic EAAT2 glutamate transporter in affected regions 14 ( Supplementary Fig. 5 online) and the failure of normal glutamate uptake of SOD1 G93A astrocytes in vitro 15 support glutamate-dependent excitotoxicity as a component of disease. Nevertheless, diminished mutant SOD1 synthesis in most astrocytes did not affect disease-dependent loss of EAAT2 from those astrocytes ( Supplementary Fig. 5 ), indicating that a reduction in glutamate transport reflects non-cell autonomous damage to astrocytes, in part, from mutant SOD1 synthesized by other cells. Our use of selective gene excision has now demonstrated that mutant SOD1 damage in both microglia 3 and astrocytes (Fig. 1g-j) accelerates later disease progression without affecting the initiation of motor neuron degeneration and phenotypic disease onset. Discovery that damage in astrocytes determines the timing of microglial activation and infiltration provides further evidence that, beyond any direct effect of mutant astrocytes on motor neurons, such astrocytes amplify an inflammatory response from microglia (including enhanced production of nitric oxide and possibly of toxic cytokines), leading to further damage to the motor neurons and accelerated disease progression through a non-cell autonomous mechanism ( Supplementary  Fig. 6 online) . These findings validate therapies, including astrocytic stem cell-replacement approaches, that aim to slow disease progression in ALS by supplementing healthy astrocytes or modulating toxicity in astrocytes to control an inflammatory response of microglia. 
